EpiGentek announces a new antibody-based blood test to detect COVID-19 in as little as 3 minutes

By: EpiGentek Group Inc.
FARMINGDALE, N.Y. - March 31, 2020 - PRLog -- EpiGentek, a NY-based biotechnology firm specializing in epigenetic assay products and services, has announced that in light of the COVID-19 global pandemic, it is launching a rapid serological test to detect for the disease. The method uses blood samples like fingertip blood and can deliver results in under 15 minutes and as fast as 3 minutes. The company, known for its fast, easy antibody-based assays, recently sent to the FDA a notice of intent to distribute the kits and expects full availability in mid-April.

The test, SeroFlash(TM) SARS-CoV-2 IgG/IgM Antibody Detection Kit, comprises of a test card that will reveal a color band to reflect negative or positive results. Based on colloidal gold immune technology, the test identifies the presence of SARS-CoV-2 antibodies. Blood samples are mixed with diluent and added to the test card with results indicated within 3 to 15 minutes. A clinical study with various serum, plasma, and whole blood samples from 267 patients demonstrated 93.7% testing accuracy, with increased accuracy of 98.9% if counting whole blood samples alone. The method has been validated for 100% negative correlation to other human coronaviruses and influenza.

William Lee, VP of Operations at EpiGentek, said, "Given our resources and expertise, we feel it's our duty to join the fight for public safety in the wake of the crisis. I'm proud that we can offer a rapid solution to healthcare professionals and organizations who are struggling to keep stock of testing kits for incoming patients."

Lee explains the goal is to make the test widely accessible by lowering handling difficulty and cost. At around $10 - $20 per test, SeroFlash(TM) does not require special analytical devices or instruments. Whereas current testing results are often delayed several days due to the need for special sample preparation and equipment, SeroFlash(TM)'s rapid turnaround time and simplicity is ideal for use at the point of care by healthcare personnel. This test also has broader implications which enables scientists to identify and confirm immunity through detection of SARS-CoV-2 antibodies. Such identification allows for the immune to return to work, anchor the economy, and help care for the vulnerable.

If you represent a laboratory or point-of-care organization capable of testing, please visit our COVID-19 resource page at https://www.epigentek.com/covid19 to learn more or to contact us with any questions.

About EpiGentek Group Inc.
EpiGentek is a New York-based biotechnology company that focuses on developing innovative technologies, services, and products as a complete and systematic solution for epigenetic related research and drug discovery. Visit the website at www.epigentek.com.

For Inquiries:
Posted By:***@epigentek.com Email Verified
Tags:COVID 19 Test
Location:Farmingdale - New York - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Page Updated Last on: Mar 31, 2020
EpiGentek News
Most Viewed
Daily News

Like PRLog?
Click to Share